A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE

Haemophilia

Volumn 22, Issue 6, 2016, Pages 957-965

  Turecek, P L ^a   Romeder Finger, S ^a   Apostol, C ^a   Bauer, A ^a   Crocker Buque A ^b   Burger, D A ^c   Schall, R ^c   Gritsch, H ^a  

^a Baxalta Innovations   (Austria)

^b Rosebank ^*  (United Kingdom)

^c IQVIA   (United States)

Author keywords

acquired haemophilia; chromogenic assay; FVIII assay; haemophilia; one stage clotting assay; PEG FVIII; porcine FVIII

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; ASSAY; CHROMOGENIC ASSAY; CONTROLLED STUDY; DRUG POTENCY; HEMOPHILIA A; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; ONE STAGE CLOTTING ASSAY; PRIORITY JOURNAL; FEMALE; HEMOSTASIS; IMMUNOLOGY; MALE; QUESTIONNAIRE;

FACTOR VIII; FEMALE; HEMOPHILIA A; HEMOSTASIS; HUMANS; MALE; SURVEYS AND QUESTIONNAIRES;

EID: 84994275833     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13001     Document Type: Article

References (37)

1. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2003; 9: 1–23.
2. Kessler CM. Advances in the Treatment of Hemophilia. Clin Adv Hematol Oncol 2008; 6: 184–7.
3. Kim YG, Park B, Ahn JO, Jung JK, Lee HW, Lee EG. New cell line development for antibody-producing Chinese hamster ovary cells using split green fluorescent protein. BMC Biotechnol 2012; 12: 24.
4. Fang H, Wang L, Wang H. The protein structure and effect of factor VIII. Thromb Res 2007; 119: 1–13.
5. Fay PJ. Factor VIII structure and function. Int J Hematol 2006; 83: 103–8.
6. Kaufman RJ. Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology. Ann Hematol 1991; 63: 155–65.
7. Lai C, Albert T, Sivakollundu S et al. Elucidation of structure and functional characteristics of OBI-1, a recombinant, porcine sequence FVIII. Haemophilia 2014; 20: 180.
8. Lillicrap D, Schiviz A, Apostol C et al. Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile. Haemophilia 2016; 22: 308–17.
9. Turecek PL, Bossard MJ, Graninger M et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie 2012; 32(Suppl 1): S29–38.
10. Weber A, Engelmaier A, Hainzelmayer S et al. Development, Validation, and Application of a Novel Ligand-Binding Assay to Selectively Measure PEGylated Recombinant Human Coagulation Factor VIII (BAX 855). Bioconjug Chem 2015; 26: 2133–42.
11. Stidl R, Fuchs S, Bossard M, Siekmann J, Turecek PL, Putz M. Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates. Haemophilia 2016; 22: 54–64.
12. Valentino LA, Cong L, Enockson C et al. The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule. Haemophilia 2015; 21: 58–63.
13. Advate European Public Assessment Report Scientific Discussion. European Medicines Agency, 2005. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/advate/581203en6.pdf. Accessed: October 31, 2014.
14. Wojciechowski P, Lai C, Xiong Y, Deer F. Overview of the structure and manufacturing process for OBI-1, a recombinant porcine sequence, factor VIII for the treatment of acquired hemophilia A. Haemophilia 2014; 20: 181.
15. Kruse-Jarres R, St-Louis J, Greist A et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 2015; 21: 162–70.
16. Kempton CL, Abshire TC, Deveras RA et al. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia 2012; 18: 798–804.
17. Hubbard AR, Dodt J, Lee T et al. Recommendations on the potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost 2013; 11: 988–9.
18. Barrowcliffe TW. Standardization of FVIII & FIX assays. Haemophilia 2003; 9: 397–402.
19. Kitchen S, Jennings I, Preston FE, Kitchen DP, Woods TA, Walker ID. Interlaboratory variation in factor VIII: C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation. Semin Thromb Hemost 2009; 35: 778–85.
20. Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation. Semin Thromb Hemost 2009; 35: 786–93.
21. Barrowcliffe TW, Cattaneo M, Podda GM et al. New approaches for measuring coagulation. Haemophilia 2006; 12(Suppl 3): 76–81.
22. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost 2002; 28: 247–56.
23. Potgieter JJ, Damgaard M, Hillarp A. One-stage vs. chromogenic assays in haemophilia A. Eur J Haematol 2015; 94(Suppl 77): 38–44.
24. Kitchen S, Blakemore J, Friedman KD et al. A computer-based model to assess costs associated with the use of FVIII and FIX one-stage and chromogenic activity assays. J Thromb Haemost 2016; 4: 757–64.
25. Santoro C, Iorio A, Ferrante F et al. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII). Haemophilia 2009; 15: 779–87.
26. Gu JM, Ramsey P, Evans V et al. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. Haemophilia 2014; 20: 593–600.
27. Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646–50.
28. Barrowcliffe TW. Factor VIII and thrombin generation assays: relevance to pharmacokinetic studies in haemophilia A. Haemophilia 2006; 12: 23–9.
29. Sommer JM, Moore N, McGuffie-Valentine B et al. Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories. Haemophilia 2014; 20: 294–300.
30. Viuff D, Barrowcliffe T, Saugstrup T, Ezban M, Lillicrap D. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 2011; 17: 695–702.
31. Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost 2016; 2: 248–61.
32. Workshop report: Characterization of new clotting factor concentrates (FVIII, FIX) with respect to potency assays used for labelling and testing of post infusion samples: European Medecines Agency, 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/07/WC500169760.pdf. Accessed: February 11, 2016.
33. Pouplard C, Ternisien C, Desconclois C, Lasne D, Aillaud MF, Caron C. Discrepancies between one stage assay and chromogenic substrate assay in patients treated with recombinant or plasma-derived FVIII and usefulness of a specific standard in ReFacto AF -treated patients. Haemophilia 2016; 22: e99–e118.
34. Sommer JM, Buyue Y, Bardan S et al. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity. Thromb Haemost 2014; 112: 932–40.
35. Kitchen S, Signer-Romero K, Key NS. Current laboratory practices in the diagnosis and management of haemophilia: a global assessment. Haemophilia 2015; 21: 550–7.
36. Kitchen S, Gray E, Mertens K. Monitoring of modified factor VIII and IX products. Haemophilia 2014; 20(Suppl 4): 36–42.
37. Kitchen S, Beckmann H, Katterle Y, Bruns S, Tseneklidou-Stoeter D, Maas Enriquez M. BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study. Haemophilia 2016; 22: e192–e199.